A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
PHASE1This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized...
Location
Nkarta Investigational Site
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
PHASE1This is a single arm, open-label, multi-center, Phase 1 study to determine ...
Status
Active Not Recruiting
Location
Colorado Blood Cancer Institute
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
PHASE1Primary objective: Safety and tolerability of NKX019, administered after ly...
Status
Enrolling By Invitation
Location
Hospital for Special Surgery
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
PHASE1This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized...
Location
Nkarta Investigational Site